Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Venadaparib in Healthy Korean, Chinese, and Caucasian Males
NCT05202912Phase 1Completed
- Sponsor
- Idience
- Start
- Jan 2022
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of venadaparib in solid tumor, gastric cancer (GC), breast cancer and 1 more (2 cohorts), sponsored by Idience. Primary endpoints: Maximum Observed Plasma Concentration and Area Under the Plasma Concentration-Time Curve from Time Zero to Time of Last Quantifiable Concentration. Started Jan 2022; status: completed.
02
Drugs
venadaparib
03
Conditions
solid tumorgastric cancer (GC)breast cancerovarian cancer
Beyond the preview
Go deeper on NCT05202912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05202912.